Walleye Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Walleye Capital’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,400	Closed	-$102K	–	5757
2024 Q3	$102K	Hold	1,400	–	–	﹤0.01%	4389
2024 Q2	$95.9K	Buy	1,400 +1,000	+250%	+$69.4K	﹤0.01%	4735
2024 Q1	$27.7K	Sell	400 -14,000	-97%	-$962K	﹤0.01%	4839
2023 Q4	$1.03M	Hold	14,400	–	–	﹤0.01%	2312
2023 Q3	$750K	Buy	14,400 +100	+0.7%	+$5.83K	﹤0.01%	2481
2023 Q2	$905K	Buy	14,300 +13,100	+1,092%	+$816K	﹤0.01%	1936
2023 Q1	$65K	Sell	1,200 -10,500	-90%	-$508K	﹤0.01%	3111
2022 Q4	$619K	Sell	11,700 -400	-3%	-$20K	0.01%	1317
2022 Q3	$563K	Buy	+12,100	New	+$632K	0.01%	1381
2020 Q1	–	Sell	-62,900	Closed	-$2.16M	–	1806
2019 Q4	$2.16M	Buy	62,900 +39,300	+167%	+$472K	0.14%	178
2019 Q3	$176K	Buy	+23,600	New	+$226K	0.01%	1248
2019 Q2	–	Sell	-3,400	Closed	-$41K	–	2134
2019 Q1	$41K	Buy	+3,400	New	+$43.4K	0.01%	1252

Other funds holding ITCI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Walleye Capital's ITCI Position: Q1 2025 in Review

Walleye Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 383,591 shares — an estimated $32M sold.

Walleye Capital first reported a position in ITCI in Q1 2019 and held it in 18 quarters. The position peaked at $32M in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

Walleye Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
Walleye Capital sold 383,591 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $32M.
Walleye Capital first reported a position in Intra-Cellular Therapies Inc. in Q1 2019 and held it in 18 quarters.
Walleye Capital's Intra-Cellular Therapies Inc. position peaked at $32M in Q4 2024.
395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Walleye Capital's 13F filing for Q1 2025, filed 14 May 2025.